

APBMT Annual Report 2023

Asia-Pacific Blood and Marrow Transplantation Group
SECRETARIAT OFFICE / DATA CENTER OF APBMT



Copyright APBMT Annual Report 2023

Worldwide Confidentiality Note: Dissemination, distribution or copying of this document or the information herein by anyone other than the approved recipient is prohibited. If you are not the intended recipient, please inform APBMT Secretariat (office@apbmt.org).

Prior approval must be sought from APBMT before releasing any data from this document publicly, and APBMT must be acknowledged as the data source. The suggested citation is : "APBMT Annual Report 2023".

This document contains information on hematopoietic stem cell transplants and cellular therapies provided voluntarily by participating countries/regions in the Asia-Pacific region. The data and its analysis are the property of APBMT. This APBMT resource is intended for use by its members and approved participating clinical and research organizations.

While all care has been taken in the compilation of this document, no responsibility can be taken for misuse of the data or for data errors that have been unintentionally included.



**Asia-Pacific Blood and Marrow
Transplantation Group
(APBMT)
Annual Report
2023**

Secretariat Office / Data Center of APBMT

**E-mail: office@apbmt.org
Website: <https://www.apbmt.org>**

Contents

Introduction

- General Overview 2023
- Bylaws
- Organizational Tree
- Principal Member List

Annual Congresses

- Guidelines for the hosting of the APBMT annual congress
- Previous and Future Congresses
- The Number of Attendees for Each Annual Congress from 2014 to 2023

Registry Committee

- APBMT Registry Committee
- Registry Committee Member List

Nursing Committee

- About Nursing Committee
- Nursing Committee Member List

Executive Board

- Executive Board Activities
- Executive Board Members

Collaboration with Other International Registries

- General Information
- History of International Scientific Symposia

Blood Cell Therapy -The Official Journal of APBMT-

- About the Journal
- Editorial Board Member List
- List of the Accepted Articles (Volume 6.)

Appendix

- Cooperate Members

Introduction

General Overview 2023

APBMT welcomed Uzbekistan as a new member in October 2023, and all 23 participating countries/regions are listed here as of December 2023.

Australia
Bangladesh
Cambodia
China
Hong Kong
India
Indonesia
Iran
Japan
Korea
Malaysia
Mongolia
Myanmar
Nepal
New Zealand
Pakistan
Philippines
Singapore
Sri Lanka
Taiwan
Thailand
Uzbekistan
Vietnam



This Annual Report is the 16th edition overall. It covers APBMT activities from January to December 2023. Although COVID-19 still influences the medical field of HSCT and cellular therapy in this region, all doctors and medical staff have made great efforts to care for patients with hematological diseases. We have entered a new era of “post-COVID-19.”

The 27th Annual Congress (APBMT 2023) was held on the hybrid platform in Semarang, Indonesia and it was a great success in terms of the number of attendees. Having built a strong foundation for APBMT over the past eight years, the Executive Board members began to hand over their positions to the next generation. Dr. Srivastava was elected as the new Chair and Dr. Okamoto accepted the position of the Immediate Past Chair. The current Executive Board has welcomed two new members and continues the transition to the future.

BYLAWS OF THE ASIA PACIFIC BLOOD AND MARROW TRANSPLANTATION GROUP (APBMT)

ARTICLE 1

Name of the Group

The Asia Pacific Blood and Marrow Transplantation Group, hereafter referred to as APBMT was established in 1990 to allow doctors, other health professionals and scientists in the Asia Pacific region involved in clinical blood and marrow transplantation and therapies related to hematopoietic stem cell transplantation to collaborate and promote high quality blood and marrow transplantation in the region.

ARTICLE 2

Incorporation

APBMT is incorporated as Corporate Juridical Person for scientific and educational purposes under the laws of Japan.

ARTICLE 3

Purpose of APBMT


The group aims to promote all aspects associated with the hematopoietic stem cell transplantation (HSCT) and related therapies in the Asia Pacific region, which includes:

- To ascertain and provide the updated status of haematopoietic stem cell transplantation (HSCT) in the Asia Pacific region.
- To steer and regulate the HSCT Registry in the Asia Pacific region (Asia Pacific Blood and Marrow Transplantation Group Registry: APBMT Registry)
- To share current knowledge of all aspects of HSCT to promote and maintain the highest standards of care, and to work towards a set of standards and accreditation of transplant units.
- To provide training opportunities in HSCT in the Asia Pacific region.
- To promote collaborative research in the Asia Pacific region.
- To collaborate with other international organizations related with HSCT
- To work as a core voting member of WBMT

ARTICLE 4

Organization

The schema of the organization in APBMT indicates below.



4. Membership Any persons involved in the treatment of recipients and donors (such as physicians, nurses, laboratory technicians, persons related to stem cell donor programs or pharmaceutical companies), who are involved in HSCT and agree with the purpose of the group can become a member (see above section). New members are admitted by submitting a membership application form and CV up to 2 pages to the Secretary Office. This application must include the signature of an APBMT member as a presenter. There are two different kinds of memberships; Scientific members (physicians, nurses, laboratory technicians, persons related to stem cell donor programs) and Corporate members (pharmaceutical and for-profit companies). Scientific members include Regular, Associate, Affiliate, Honorary and Emeritus members. All members have to pay annual membership fees except for the Honorary and Emeritus members.

4.1 Regular members

Regular members consist of members from medical fields with an M.D. or Ph.D sufficient experiences and demonstrated in hematopoietic stem cell transplantation / cellular therapy. A proposed new member must provide a membership application form and CV that includes professional qualification, work experiences, current employment and place of work to the Secretariat Office. Regular members must agree to abide by the regulations of APBMT, to participate in scientific endeavors of APBMT, to have good ethical and moral standards as well as no criminal record, as expected by professional societies. Regular members can attend the Business meeting but do not have voting right. Regular members can elect and can be elected as Scientific Committee members within each country.

4.2 Associate members

Individuals with and M.D. or Ph.D who do not meet the criteria for regular membership will become Associate members. Associate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

4.3 Affiliate members

Professionals who are members of HSCT / cellular therapy team or interested in HSCT / cellular therapy (NP, PA, Pharm D, RN etc.) are eligible to be Affiliate members. Affiliate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

4.4 Emeritus members

Anyone in APBMT who has contributed in a significant way to its development is eligible to become Emeritus Members. Emeritus members are nominated by the Executive Board and are approved by the Scientific Committee at the business meeting. Emeritus Members are eligible to participate in the business meeting.

4.5 Honorary members

Individuals who are not an APBMT member but have contributed to the establishment or the development of APBMT are eligible to become an Honorary member. Honorary members are nominated by the APBMT members and are approved by the Scientific Committee at the business meeting. Honorary

members are ineligible to participate in the Business meeting.

4.6 Corporate members

Representatives of commercial and for-profit companies can become Corporate members. Corporate members cannot attend the Business meeting and do not have voting right. Applicants are required to submit a membership application form and CV to the Secretariat Office.

4.7 Scientific Committee

Scientific Committee is the supreme decision-making body in APBMT. Each country can elect and nominate 1 voting member as the country representative. The vote is casted by the country representative but this right may be transferred to a designated substitute. If there is more than one nominee from one country, the Scientific Committee can vote to select one candidate. The names of the current members of scientific committee are listed and updated annually. The Chairman of the Executive Board, who also serves as the Chairman of the Scientific Committee, has the deciding vote if the vote is otherwise tied.

New Scientific Committee members need to be recommended by the current members of Scientific Committee among the members of the Regular Members and to get approval in the business meeting. Decisions are taken by majority voting (One vote/one country). A proposed new member must provide a brief CV up to 3 pages. The criteria to be a Scientific Committee Member include proven medical and/or scientific experience in HSCT; willingness to committee and participate in scientific endeavors of APBMT; no criminal record, good ethical and moral standards as expected by professional societies.

The Scientific Committee member has the following rights and obligations: 1) To attend the Annual Business Meeting; 2) To elect Executive Board members; 3) To decide on admission of new members; 4) To decide the annual fee for APBMT membership; 5) To make final decision on APBMT policies and its finance.

A Scientific Committee member will lose his/her rights as a representative of his/her country/region when he/she leaves his/her original country/region permanently.

4.8 Executive Board

The Executive Board of APBMT steers the group for administration and all decisions that need to be taken for functioning of the organization in accordance

with the constitution and bylaws of the organization. The Executive Board is responsible for all running operations and decisions that are not due to be taken by the Scientific Committee at the annual meeting. The Executive Board, appointed by the Scientific Committee, will act on behalf of all members for regular decisions during the period between Scientific Committee meetings. During this period, the Scientific Committee need not be consulted unless a decision would affect the bylaws or contravene a decision previously made by the Scientific Committee. The Executive Board consisted of regular members (only one member permitted from one country) elected from the Scientific Committee. The maximum number of members of the Executive Board is nine. The Chairman of Executive Board represents APBMT.

4.9 Officers of the Executive Board

1. Scientific Committee elects a) one Chairman of Executive Board, b) one Vice Chairman of Executive Board, c) several other Members of Executive Board including one Secretariat / Treasurer. The members of the Executive Board are elected by the business meeting, and serves for two years and may be re-elected for another term of two years.
2. The function of the Chairman of Executive Board is to promote and coordinate all activities of APBMT. These include fund raising, coordination of Working Group activities, giving suggestions to the organizers of the annual meeting, and negotiations with other organizations on behalf of APBMT.
3. The Vice Chairman supports the Chairman and will perform the duties of the Chairman in the absence.

4.10 Secretariat/Treasurer

Secretariat / Treasurer shall oversee the maintenance of a permanent record of APBMT. The Secretariat / Treasurer shall have oversight of the budget of APBMT. The Secretariat / Treasurer Office works for the development and the maintenance of the group under the collaboration with the Chairman of Executive Board, the Chairman of the next annual congress, and the members of Executive Board and Scientific Committee.

ARTICLE 5

Committees and Working Groups

5.1 Committees

APBMT will have the following Standing Committees to help with its work.

1. Membership Committee
2. Registry Committee
3. Program Committee
4. Nuclear Accident Management (NAM) Committee
5. Editorial Board of the Blood Cell Therapy, the Official Journal of APBMT

Each of these committees will have a specific term of reference.

5.2 Working Groups

The aim of Working Groups is to enhance research in focused areas. The Executive Board and Scientific Committee of APBMT determine the formation of Working Groups as required. The application of the new Working Group and its chair person is approved by the members of the Scientific Committee in the Business Meeting (see Annex). The chair person of each Working Group is elected for three years and may stand for reelection once. The substructure of the Working Group is defined by the chair person in consultation with the Executive Board. Regular Members are encouraged to participate in one or more Working Groups according to their particular interests. The Working Group chair person must submit annual activity reports to the Scientific Committee and the Executive Board. The chairperson should adhere to the Working Group responsibilities, which are specified separately from the bylaws.

ARTICLE 6

Meetings

6.1 Annual Congress

Any countries participating in APBMT can propose to be a host country of the Annual Congress. Host country of the future Annual Congresses will be decided by the Scientific Committee. The President of the next annual congress cooperates with the Executive Board for the year preceding the annual congress. The format of the meeting is to be standardized (see Annex section below).

6.2. Business Meeting

The Scientific Committee will open the Business Meeting at least once a year. One of them will be held during the annual meeting. It is co-chaired by the Chairman of the Executive Board and the President of the Annual Congress. The Board may establish subcommittee / working party as the need arises.

6.3 Board Meeting

The Executive Board of the APBMT shall meet in person at the annual meeting. It is presumed that all members will attend this meeting unless there are unavoidable personal circumstances. In addition, the board will meet via conference calls every 4-8 weeks, as needed. All members are expected to attend all scheduled board meetings.

ARTICLE 7

7.1 APBMT Registry

A major activity of the APBMT will be to guide the development of national registries in each country. This data will then be collected into the combined APBMT registry in formats compatible with other international registries. Both activities and outcome data will be collected every year.

7.2 Annual Report

The list of registrants and summary of analyses are published in the APBMT Annual Report of each year, which is distributed to the APBMT member and related persons / organizations. The results published in the APBMT Annual Report is confidential, however, it can be quoted after written approval from APBMT and accompanied by proper acknowledgement.

7.3 Rules on the use of the Registry data

Data are restricted to publication in a scientific article and / or presentation at academic meetings. APBMT contributions must be appropriately acknowledged in all presentations and publications prior to the release of the data and analyses. Written Applications for these purposes are limited to Scientific Committee Members, Working Groups and the Data Center of APBMT for the time being. Written requests from other academic organizations or commercial companies will be assessed and if approved a cost recovery will be charged depending on the amount of work. Confidentiality of source information will be protected in accordance with the laws of individual centres and countries. An application form is attached as a separate sheet. The Registry Committee will evaluate all applications and approval made after consultation with the Executive Board.

ARTICLE 8

Finance

8.1 Membership Fees:

All the Regular Members are required to pay annual membership fees on an individual basis (see Annex). The members who paid the membership fees can receive up-to-date information including the survey data from APBMT office and also may have the advantage of discount of the registration fees at annual congress.

8.2 Statement of accounts of annual APBMT congress

An audited statement of accounts must be prepared by the organizing committee for each annual APBMT meeting within one year of its completion and submitted to the APBMT Headquarters and presented at the annual business meeting.

ARTICLE 9

Amendments

9.1 These Bylaws may be amended at any annual business meeting of the Scientific Committee. Amendments to the Bylaws may be proposed in writing to the Executive Board and must be submitted at least ninety days prior to the annual meeting. In addition, the Executive Board may initiate proposed amendments to the Bylaws.

The proposed amendments, together with the Executive Board's recommendation, shall be distributed to members of the Scientific Committee at least thirty days before the annual meeting at which it is to be considered. To be adopted, an amendment must be approved by at least two thirds of voting at the annual meeting.

9.2 Annexures may be amended by the Executive Board, (with a minimum of two third majorities of the members of the Executive Board) and report to the Scientific Committee.

Annexures:

1. Committees - Terms of Reference to be determined.
2. Working Groups - Terms of Reference to be determined.
3. Annual Congress – Format of the meeting to be formulated
4. The APBMT Registry
5. Financial Issues

6. The Scientific Committee members: In addition to the criteria to be a Scientific Committee Member described in APBMT Bylaw (4.7 Scientific Committee), the candidate must have served as a regular member for the past three years with the consecutive payment of annual membership fee. No term limits are set for Scientific Committee Members. However, the members are required to participate in at least 2 out of 4 most recent APBMT Annual Congress, and consecutively pay annual membership fee in order to maintain their membership. In addition, their willingness of serving as Scientific Committee Members is to confirm every two years. No limits are set for the maximum number of Scientific Committee members in each country/region participating APBMT
7. Others
(Detailed rules such as payments and duties for the members are described in the annexure)

Establishment: October 1, 2009

History of revision:


December 31, 2010

October 31, 2015

November 1, 2016 (Annexure 6 was added.)

August 31, 2019

Organizational Tree of APBMT



Principal Member List

Executive Board members

Alok Srivastava (Chair, India)	David D Ma (Australia/New Zealand)	He Huang (China)
Amir Ali Hamidieh (Iran)	Jong Wook Lee (Korea)	Gin Gin Gan (Malaysia)
Bor-Sheng Ko (Taiwan)	Damai Santosa (Indonesia)	Shinichiro Okamoto
		(Immediate Past Chair, Japan)

*Scientific Committee Members (*Executive Board members)*

David D Ma (Australia/New Zealand) *	John Moore (Australia/New Zealand)	Mohiuddin Khan (Bangladesh)
Mafruha Akter (Bangladesh)	Pheng Bora (Cambodia)	He Huang (China) *
Xiao-Jun Huang (China)	Kai-yan Liu (China)	Jian Ouyang (China)
Jianmin Wang (China)	Tong Wu (China)	Mei Zhang (China)
Albert Lie (Hong Kong)	Shashikant Apte (India)	Sharat Damodar (India)
Alok Srivastava (India) *	Auro Viswabandya (India)	Navin Khattray (India)
Damai Santosa (Indonesia) *	Amir Ali Hamidieh (Iran) *	Mani Ramzi (Iran)
Yoshiki Akatsuka (Japan)	Shuichi Taniguchi (Japan)	Shinichiro Okamoto (Japan) *
Takanori Teshima (Japan)	Tai-ju Hwang (Korea)	Hyoung Jin Kang (Korea)
Hoon Kook (Korea)	Jong Wook Lee (Korea) *	Jong-Ho Won (Korea)
Gin Gin Gan (Malaysia) *	Otgonbat Altangerel (Mongolia)	Khishigjargal Batsukh (Mongolia)
Aye Aye Gyi (Myanmar)	Sein Win (Myanmar)	Bishesh Sharma Poudyal (Nepal)
Tahir Sultan Shamsi (Pakistan)	Carmella Bingcang (Philippines)	William YK Hwang (Singapore)
Mickey Koh (Singapore)	Aloysius Ho (Singapore)	Lallindra Gooneratne (Sri Lanka)
Bor-Sheng Ko (Taiwan) *	Hsiao Liang-Tsai (Taiwan)	Kai-Hsin Lin (Taiwan)
Jih-Luh Tang (Taiwan)	Chi-Cheng Li (Taiwan)	Udomsak Bunworasate (Thailand)
Suradej Hongeng (Thailand)	Artit Ungkanont (Thailand)	Chi Dung Phu (Vietnam)

Emeritus Members

Suresh H Advani (India)	Shigetaka Asano (Japan)	Lu Xian Cao (China)
Po-Min Chen (Taiwan)	Ardeshir Ghavamzadeh (Iran)	Surapol Issaragrisil (Thailand)
Saengsuree Jootar (Thailand)	Chun Choo Kim (Korea)	Dong Jip Kim (Korea)
Yoshihisa Kadera (Japan)	Dao-Pei Lu (China)	Tohru Masaoka (Japan)
Tan Binh Nguyen (Vietnam)	Philip Rowlings (Australia/New Zealand)	Tapan K Saikia (India)
Patric Tan (Singapore)	Ming Yao (Taiwan)	

Note: As of the end of 2023

Annual Congresses

Guidelines for the hosting of the APBMT annual congress

Planning and preparation

- APBMT Annual Congress is organized by APBMT in collaboration with the host country/society each year through an Organizing Committee and a Scientific Program Committee (SPC).
- The chair of the APBMT Board will be a Co-President of the Annual Congress along with a Co-President nominated by the host country.
- Both committees will function as per a schedule drawn up by the APBMT Secretariat for targets to be achieved to the dates of the congress.
- The Organizing Committee will have two Co-chairs - Chair of the APBMT Board/Board nominee with a Co-chair from the host country/society, and the equal number of members nominated by the APBMT Board and the host country/society.
- The Scientific Program Committee (SPC) of Congress will have two co-chairs - one local and one APBMT Executive Board (EB) nominated along with an equal number of local and EB nominated international members.

The scientific program will be planned according to the standard format:

- 1st day for APBMT standing committees and working group meetings- Industry symposia / CME program or educational symposia followed by 2 ½ days of the scientific program.
- The program should consist of three major tracks for physicians, nurses, and other specialists (such as laboratory diagnostics, cell and graft manipulation, pharmacists)
- The program should contain both educational sessions and sessions covering recent topics/advances in hematopoietic cell transplantation and related fields.
- Each session has a theme on which there could be 3-4 talks in up to 90min.
- The speakers of each topic should be decided by SPC with the invitation letters to be sent by the Co-Chairs of SPC.
- Try to recruit speakers from APBMT participating countries/regions as much as possible (at least 50%) – giving representation to as many countries from Asian-Pacific (AP) regions AP as possible. Criteria for selection of speakers to be defined and followed.
- No AP country/region should have more than 10% of the total number of speakers from Asian Pacific regions in the entire Scientific Program; however, it is acceptable for a host country to have more speakers depending on their suitability but not exceeding 20% of the total.

- The term “speaker” here is determined as the one listed in the Scientific Program (including Plenary and Educational Session) prepared by the SPC but excluding sponsored symposia.
- The meeting should be organized as a hybrid meeting but with major emphasis on a physical meeting when circumstances permit.

Funding

- APBMT office may directly collect funding support from the international division of a multinational company (MNC), and the local host country will collect the support from domestic divisions of MNCs / local companies.
- The overall cost of hosting the Annual Congress will be shared between APBMT and the host country in the same proportion as the total funds collected from all sources.
- Left over funds after meeting all costs of the Annual Congress will be shared between APBMT and the host country in the same proportion as the overall fund collected.
- The budget for the Annual Congress should therefore be jointly decided between APBMT and the host country through the Organizing Committee and the Co-Presidents.

After the congress

- The hosting country must submit the followings to APBMT Secretariat after the meeting
 - Generate and report the financials
 - Submit a list of all attendees (names, countries and email address if possible)
 - Provide all abstracts for uploading on the Blood Cell Therapy website. The permission should be obtained from presenters when they were submitted
 - Provide photos and PowerPoint presentations made during the Congress for uploading the APBMT website after due permissions from the speakers.

Previous Congresses

No	Year	City	Presidents
1 st	1990	Beijing	Lu Xian Cao
2 nd	1991	Nagoya	Tohru Masaoka
3 rd	1992	Osaka	Tohru Masaoka
4 th	1994	Fukuoka	Tohru Masaoka
5 th	1996	Seoul	Dong Jip Kim
6 th	1998	Taipei	Yao-Chang Chen
7 th	2000	Bangkok	Surapol Issaragrisil
8 th	2002	Mumbai	Suresh Advani
9 th	2004	Tehran	Ardeshir Ghavamzadeh
10 th	2005	Hangzhou	Dao-Pei Lu
11 th	2006	Nagoya	Yoshihisa Kodera
12 th	2007	Beijing	Dao-Pei Lu
13 th	2008	Taipei	Po-Min Chen
14 th	2009	Seoul	Chun-Choo Kim
15 th	2010	Phuket	Saengsuree Jootar
16 th	2011	Sydney	David Ma / Philip Rowlings
17 th	2012	Hyderabad	Tapan K Saikia / Alok Srivastava
18 th	2013	Ho Chi Minh City	Tan Binh Nguyen
19 th	2014	Hangzhou	He Huang / Xiaojun Huang
20 th	2015	Okinawa	Shinichiro Okamoto
21 st	2016	Singapore	William YK Hwang / Chng Wee Joo / Aloysius Ho
22 nd	2017	Tehran	Ardeshir Ghavamzadeh
23 rd	2018	Taipei	Ming Yao / Jih-Luh Tang
24 th	2019	Busan	Jong Wook Lee / Jong-Ho Won
25 th	2020	APBMT/ISBMT (Virtual)	Mammen Chandy/ Alok Srivastava

26 th	2021	Chiang Mai (Hybrid)	Artit Ungkanont
27 th	2022	Kochi (Hybrid)	Alok Srivastava/Shinichiro Okamoto
28 th	2023	Semarang (Hybrid)	Damai Santosa/Shinichiro Okamoto

Future Congresses

- The 29th Annual Congress
Oct. 10 (Thu) - 13 (Sun), 2024
Singapore
Congress Presidents: Aloysius Ho / Alok Srivastava

The Number of Attendees for Each Annual Congress from 2014 to 2023


2014(CHINA)		2015(JAPAN)		2016(SINGAPORE)		2017(IRAN)		2018(TAIWAN)	
China	646	Japan	159	Singapore	234	Iran	565	Taiwan	330
Japan	31	China	186	China	116	China	32	China	90
Taiwan	24	Taiwan	51	Japan	62	USA	4	Japan	66
Korea	16	Korea	41	Korea	44	Germany	4	Korea	33
United States	11	Singapore	23	Taiwan	28	Japan	3	Singapore	32
India	9	Hong Kong	17	India	25	Thailand	3	Vietnam	29
Singapore	9	Vietnam	16	USA	22	Qatar	3	Thailand	21
Australia	7	India	11	Thailand	21	France	2	Hong Kong	18
Mongolia	7	Thailand	11	Hong Kong	19	Italy	2	USA	15
UK	5	Indonesia	9	Malaysia	19	Belgium	1	Philippines	13
Hong Kong	4	USA	7	Bangladesh	15	India	1	India	11
Philippines	4	Malaysia	6	Vietnam	15	Turkey	1	Malaysia	8
Vietnam	4	Australia	5	Australia	13	UK	1	Indonesia	7
France	3	Philippines	5	Iran	11	Malaysia	1	Australia	6
Iran	3	UK	4	Philippines	10	Sri Lanka	1	Bangladesh	6
Thailand	3	Germany	2	Germany	9	Switzerland	1	Sri Lanka	5
Germany	2	Iran	2	Sri Lanka	6	Total	625	UK	5
Myanmar	2	Sri Lanka	2	UK	6		%	Germany	4
Pakistan	2	Bangladesh	1	France	4	Domestic	90	Canada	3
Bangladesh	1	Cambodia	1	Mongolia	4	Foreign	10	Mongolia	3
Indonesia	1	Canada	1	Indonesia	3			Myanmar	3
Lebanon	1	France	1	Ireland	3			Romania	2
Malaysia	1	Italy	1	Italy	3			Cambodia	1
South Africa	1	Mongolia	1	Cambodia	2			France	1
Spain	1	Myanmar	1	Myanmar	2			Iran	1
Sri Lanka	1	Pakistan	1	Qatar	2			Netherlands	1
Total	799	Switzerland	1	Belgium	1			North Korea	1
	%	Missing	1	Canada	1			Spain	1
Domestic	81	Total	567	Nepal	1			Total	716
Foreign	19		%	New Zealand	1				%
		Domestic	28	Spain	1			Domestic	46
		Foreign	72	Switzerland	1			Foreign	54
				Total	704				
					%				
				Domestic	33				
				Foreign	67				

2019(KOREA) ※		2020(INDIA) ※ ※		2021(THAILAND) ※ ※ ※		2022(INDIA) ※ ※		2023(INDONESIA)	
Korea	762	India	822	Thailand	525	India	446	Indonesa	484
China	125	China	173	Singapore	48	Singapore	19	India	40
Japan	47	Philippines	98	Japan	31	Vietnam	19	Japan	24
Taiwan	46	Vietnam	68	China	26	Japan	16	Philippines	21
India	37	Japan	67	India	18	Thailand	7	Vietnam	20
Indonesia	22	Singapore	36	Hong Kong	17	Hong Kong	5	Malaysia	18
Singapore	22	Korea, South	28	Malaysia	17	Indonesia	5	Singapore	17
Malaysia	17	Burma	27	Australia	11	Austria	4	Myanmar	9
USA	17	Iran	26	Bangladesh	11	China	4	China	8
Vietnam	16	Malaysia	23	Vietnam	11	Malaysia	4	South Korea	8
Germany	11	Australia	21	Philippines	10	USA	5	Bangladesh	7
Hong Kong	10	Thailand	20	USA	9	Pakistan	3	Thailand	3
Thailand	9	Bangladesh	17	UK	8	South Korea	3	Austria	3
Iran	8	Pakistan	16	Indonesia	7	Spain	3	Taiwan	3
Mongolia	8	Saudi Arabia	12	Korea	7	Germany	2	Uzbekistan	3
Pakistan	8	United Kingdom	12	Taiwan	5	Iran	2	USA	2
Philippines	7	Taiwan, China	11	Germany	4	Poland	2	Iran	2
Australia	5	United States	10	France	2	Taiwan	2	Brazil	2
Egypt	3	Germany	9	México	2	Brazil	1	Sri Lanka	2
France	3	Sri Lanka	9	Argentina	1	Canada	1	Germany	1
Turkey	3	Hong Kong, China	8	Austria	1	Israel	1	Russia	1
UK	3	Indonesia	6	Canada	1	Italy	1	Turkey	1
Switzerland	2	Mongolia	6	Iran	1	Jordan	1	UK	1
Spain	2	Canada	4	Italy	1	Myanmar	1	Total	680
Bangladesh	2	France	3	Myanmar	1	Philippines	1		%
Austria	1	Italy	2	Pakistan	1	Sri Lanka	1	Domestic	71
Brazil	1	Nepal	2	Portugal	1	Total	559	Foreign	29
Cambodia	1	Belgium	1	UAE	1		%		
Canada	1	Cambodia	1	Total	778	Domestic	80		
Italy	1	Ireland	1		%	Foreign	20		
Myanmar	1	Netherlands	1	Domestic	67				
Nepal	1	Sweden	1	Foreign	33				
Netherlands	1	Switzerland	1						
Poland	1	United Arab Emirates	1						
Sri Lanka	1	Total	1543						
Uzbekistan	1		%						
Total	1206	Domestic	53						
	%	Foreign	47						
Domestic	63								
Foreign	37								

*APBMT 2019 with ICBMT 2019 (International Congress of Blood and Marrow Transplantation)

**APBMT 2020&2022 with ISBMT (Indian Society for Blood & Marrow Transplantation)

***APBMT 2021 with TSH (Thai Society of Hematology)



Registry Committee

APBMT Registry Committee

APBMT has long collected HSCT activity and outcome data through the APBMT Data Center. In order to promote and accelerate the data collection, APBMT decided to establish the Registry Committee in October 2014 which officially became operational in October 2015. The APBMT Data Center was integrated into the Committee.

In 2023, the Committee revised the Protocol for starting to collect the number of cellular therapies for the future. The words “hematopoietic cell transplantation and related therapy” were also revised to “hematopoietic cell transplantation and cellular therapy (TCT).” From this year, the Data Center has split the Activity Survey form (HSCT performed in 2021) into two forms, one for adults and one for pediatrics.


Tasks for the Committee:

- Perform the annual APBMT Activity Survey and Outcome Registry
- Support data collection in participating countries/regions
- Manage and analyze the collected data
- Optimize the data usage
- Support clinical researches using collected data
- Collaboration with other societies for research

[About Activity Survey]

The APBMT Activity Survey has been performed annually since 2007 (HSCT data from 2005). This survey collects the number of transplantations sorted by the donor sources and diseases in each country/region.

The following figure shows how the data is collected.



The method of submission is different in each country/region.

As shown in the figure above, data from China, India, Japan, Korea, Malaysia, and Taiwan was submitted through their respective national registry. Data in Iran was submitted from the Ministry of Health. The Australasian Bone Marrow Transplant Recipient Registry (ABMTRR) submitted the national data for Australia and New Zealand. In Bangladesh, Indonesia, Myanmar, the Philippines, Sri Lanka, and Thailand, data was collected by a designated contact person and submitted to Data Center. Data Center has direct contact with significant transplantation centers and receives data from Hong Kong, Mongolia, Nepal, Pakistan, Singapore, Uzbekistan, and Vietnam. Data Center compiles all data collected in each of these seven countries/regions, and gathered data is available for each country/region to use as national data.

The results of the Activity Survey can be found on the APBMT website:


<https://www.apbmt.org/research/registry/survey>

[About Outcome Registry]

APBMT Registry Committee and Data Center have been collecting the HSCT outcome data of each patient. The basic dataset structure is called the Least Minimum Dataset (LMD), and three methods are available for sending data to Data Center depending on the situation in each country/region.

- The simplified Excel forms made by APBMT Data Center based on the EBMT MED-A or the CIBMTR TED
- Receiving data from CIBMTR through data transfer agreements, which were established between APBMT and CIBMTR and between APBMT and some centers that submitted Outcome Data to CIBMTR
- The electronic data capture (EDC) system using REDCap®

When the Registry/Society in participating counties/regions starts to submit HSCT outcome data to APBMT, a Non-Disclosure Agreement (NDA) is signed between APBMT and the Registry/Society when requested. In addition, APBMT Registry Committee stipulates detailed rules for data usage so that the submitted data will not be disclosed without the consent of the Committee.



*The following countries/regions are building up their systems for submitting outcome data: China, Iran, Korea, Uzbekistan, and Thailand.

Registry Committee Member List

	Name	Country/Region
Chairperson	Yoshiko Atsuta	Japan
Deputy Chairpersons	Anthony Dodds	Australia/New Zealand
	Aloysius Ho	Singapore
Members	Mafruha Akter	Bangladesh
	Pheng Bora	Cambodia
	Xiao Jun Huang	China
	Liu Kaiyan	China
	Lv Meng	China
	Joycelyn Sim	Hong Kong
	Vincent Lee	Hong Kong
	Alok Srivastava	India
	Kavitha M.L	India
	Damai Santosa	Indonesia
	Amir Hamidieh	Iran
	Shinichiro Okamoto	Japan
	Yachiyo Kuwatsuka	Japan
	Joon Ho Moon	Korea
	Kim Wah Ho	Malaysia
	Batsukh Khishigjargal	Mongolia
	Aye Aye Gyi	Myanmar
	Bishesh Poudyal	Nepal
	Tasneem Farzana	Pakistan
	Marjorie Rose Bravo	Philippines
	Prasad Abeysinghe	Sri Lanka
	Devinda Jayathilake	Sri Lanka
	Bor-Sheng Ko	Taiwan
	Hui-Fen Chiang	Taiwan
	Po-Nan Wang	Taiwan
	Ming Yao	Taiwan
	Artit Ungkanont	Thailand
	Suradej Hongeng	Thailand
	Huynh Van Man	Vietnam
	Phu Chi Dung	Vietnam
Data Center	Minako Iida	Japan
	Yukari Nakao	Japan
	Shinobu Herron	Japan

Note: As the end of October 2023

Nursing Committee

Nursing Committee

About the Committee: The APBMT Nursing Committee elected Ms. Lucas as a new Chair and launched their activity in a new organization in 2023. They nominated a few core members in each country/region and held the 1st web conference on February 6, 2023. After finalizing the committee's terms, they created the Scientific Program of the Nurse Meet for the APBMT 2023 Annual Congress in Semarang and successfully held the one-day program. They also held the 1st in-person meeting there on October 27. They discussed that to promote excellence in education, patient care, and research in nursing in the HSCT/CT field in the AP region, they will work to expand their activity in collaboration with all members.

Nursing Committee Member List

	Name	Country/Region
Chair	Amalorpavamari Lucas	India
Vice Chair	Jordan Chung Cheng Hwang	Singapore
Members	Annabel Mary Horne	Australia
	Nabin Karki	Australia
	Amanda McLaughlin	Australia
	Runa Akter	Bangladesh
	Yan Xia	China
	Aiyun Jin	China
	Ting Wang	China
	Xiaoyu Zhou	China
	Wing Sze Yuen	Hong Kong
	Meera Sharad Achrekar	India
	Sangeetha Samuel	India
	Zeinab Nikfetrat	Iran
	Leila Hejazipour	Iran
	Reiko Yamahana	Japan
	Hisayo Doi	Japan
	Miho Suzuki	Japan
	Hye Youn Lee	Korea
	Ji-Na Bok	Korea
	HyangSeon Kim	Korea
	Zulaili Yunus	Malaysia
	Normal Arshad	Malaysia
	Yee Nwe Htun	Myanmar
	Puja Kshetri	Nepal
	Dalugama Mudiyansele Deepthika Kumari Gunawardhana	Sri Lanka
	Meng-Kuan Chiang	Taiwan
	Minh Huynh Van	Vietnam

Note: As the end of 2023

Executive Board

Executive Board Activities

For smooth management of the international society, executive board members have official web conferences every month and ad-hoc web conferences as necessary.

The main topics discussed in the Executive Board web conferences:

- Preparation of the Annual Congress in collaboration with the host country/region
 - Making up the scientific program
 - Nomination of speakers
 - Management of funding
- Nominating the host country/region for the upcoming annual congress
- Expansion of membership, including the EB members
- Sponsorship contracts with the third parties/companies
- Collaboration with ASTCT, EBMT, WBMT, and other related societies in the field of HSCT/CT
- Membership control
 - Review of application forms for new membership
 - Membership fees
 - Dual membership with ASTCT
- Solving the problems with advice to each committee

Executive Board Members



Alok Srivastava
Chair
India



Jong-Wook Lee
Korea



David Ma
Australia



Amir Hamidieh
Iran



He Huang
China



Gin Gin Gan
Malaysia



Bor-Sheng Ko
Taiwan



Damai Santosa
Indonesia



Shinichiro Okamoto
Immediate Past Chair
Japan

Note: As of the end of June 2023

Collaboration with Other International Registries

WBMT

ASTCT

EBMT

WBMT (Worldwide Network for Blood & Marrow Transplantation)

APBMT is one of the founding societies of WBMT and has collaborated with other member societies such as CIBMTR, EBMT, and WMDA to operate WBMT since 2007.

Dr. Yoshihisa Koderu (Japan) and Dr. Jeff Szer (Australia) have served as president of WBMT. Many members in APBMT played important roles in the Standing Committees in 2020, with Yoshihisa Koderu acting as Co-Chair of the Transplant Centre/Recipient Committee and Yoshiko Atsuta serving as Co-Chair of the Accreditation Committee (AHCTA).

In addition, APBMT Data Center has submitted the Activity Survey data every year to contribute to the WBMT Global Transplant Activity Survey.

ASTCT (American Society for Transplantation and Cellular Therapy)

After exchanging memorandums of understanding for dual membership on August 23, 2018, APBMT and ASTCT implemented the dual membership. APBMT members who applied for this membership can receive many benefits from ASTCT. APBMT and ASTCT will continue to collaborate in the future.

EBMT (European Society for Blood and Marrow Transplantation)

APBMT has been collaborating with EBMT on many projects for a long time (booth set up at the EBMT annual meeting, advice from the JACIE members to formulate the APBMT Center Standards, the nomination of speakers for EBMT-sponsored webinars, etc.) APBMT receives valuable advice from EBMT on managing the society, and we will continue working together.

History of International Scientific Symposia

2023

October, APBMT 2023 hybrid (Indonesia)

Presidential Symposium: Fostering the next generation transplant physicians

Chairpersons: A. Srivastava, D. Santosa

- APBMT perspective (S. Okamoto)
- ASTCT perspective (MA. Perales)
- EBMT perspective (A. Sureda)
- LABMT perspective (A. Karduss)

2022

October, APBMT 2022 hybrid (India)

Presidential Symposium: Activity and Regulation of Cellular Therapies

Chairpersons: S. Okamoto, A. Srivastava

- EBMT perspective (A. Sureda)
- ASTCT perspective (M. Perales)
- WBMT perspective (D. Niederwieser)
- APBMT perspective (S. Okamoto)

February, WBMT 2022 hybrid (Pakistan)

Quality Assurance in HSCT Centers

Chairpersons: A. Seber, T. Mahmood Satti

- Overview and principles of quality systems in HSCT centers (A. Alseraihy)
- How to get an HSCT program accredited? (S. Okamoto)
- Where do we first start? From following standards to successfully obtaining accreditation (A. Kondo)

February, WBMT 2022 hybrid (Pakistan)

Patient/Donor Registration and Outcome Database

Chairpersons: Y. Atsuta, F. Alfraih, M. Ayaz Mir,

- The value of a transplant activity survey (H. Baldomero)
- The value of outcome databases (M. Pasquini)
- The APBMT Registry (M. Iida)

2021

October, APBMT 2021 hybrid (Thailand)

Presidential Symposium: Design the future of HCT Societies

Chairpersons: S. Okamoto, A. Ungkanont

- EBMT perspective (N. Kroger)
- ASTCT perspective (S. Davies)
- WBMT perspective (H. Greinix)
- APBMT perspective (S. Okamoto)

July, FACT/WBMT Webinar

Quality and Accreditation for Cellular Therapy: A Global Perspective

- Establishing an HSCT Program: Essential Requirements (D. Niderwieser)
- Development of a Quality Program in the Asia-Pacific Region (A. Srivastava)
- FACT-JACIE Accreditation in Latin America (C. Bachier)

June, EBMT Summit on COVID-19

Clinical Impact and management in HSCT patient I, Activity impact and clinical outcome

Chairs: P. Ljungman, M. Mikulska

- EBMT experience (P. Ljungman)
- USA experience: COVID19: Clinical Experience at Memorial Sloan Kettering Cancer Center (G. Papanicolau)
- Asian Pacific BM Society experience (APBMT) (W. Hwang)

April, WBMT/EBMT Webinar

Haplo-Identical HSCT, Methods and Practices Around the Globe

Moderators: H. Greinix, N. Kröger

- Haploidentical HSCT practice in Europe (A. Bacigalupo)
- Haploidentical HSCT practice in Asia (XJ. Huang)
- Haploidentical HSCT practice in North America (L. Luznik)

March, EBMT (virtual)

Joint session ASTCT/CIBMTR/APBMT: Transplantation and Cell Therapy During Pandemics

Co-Charis: N. Kröger, S. Davies, M. Riches, A. Srivastava

- US Experience: Pandemics and Transplantation/Cell therapy (A. Waghmare)
- The CIBMTR COVID Experience: Challenges for research and how COVID has changed transplant practice (M. Riches)
- The IDWP-EBMT COVID 19 Experience (R. Cámara)

- Asian-Pacific Experience: Allo-HSCT and CAR-T cell treatment during COVID 19 pandemic (Y. Hu)

February, ASTCT (Digital Experience)

WBMT Concurrent: Transplant During a Worldwide Crisis: Lessons Learned Across the World

Co-Chairs: W. Saber, M. Aljurf

- The Latin American Bone Marrow Transplantation Group (LABMT) Experience (A. Seber)
- HSCT Challenges and Solutions Under COVID-19: The Experience from China (X. Huang)
- The Eastern Mediterranean Blood and Marrow Transplantation (EMBMT) Group Experience (RE. Fakih)

2020

October, APBMT 2020 virtual (India)

Presidential Symposium on HSCT and Covid-19

Chairpersons: S. Okamoto, N. Kroeger, A. Srivastava

Moderator: S. Damodar

- HSCT in the Covid-19 Era- the Chinese Experience (H. Huang)
- Practice of HSCT in North America in COVID-19 Era (N. Majhail)
- Practice of HSCT in Europe in COVID-19 Era (P. Ljungman)
- Managing HSCTs in the context of COVID-19 pandemic - A LMIC perspective (S. Damodar)

May, WBMT Live Webinar (Online)

COVID-19 and stem cell transplantation, a Worldwide perspective:

Moderators: Y Kodaera, S Galeano

- Management of donors during the pandemic (F. Alfraih)
- Transplant recipients; COVID-19 guidelines and real-world (C. Machado)
- Chinese experience (H. Huang)
- Data from the EBMT registry during COVID-19 (P. Ljungman)
- Chimeric Antigen Receptor T Cell Therapy during COVID-19 (MA. Perales)

Blood Cell Therapy

The official journal of APBMT



Blood Cell Therapy

The official journal of APBMT

Blood Cell Therapy is the official journal of Asia-Pacific Blood and Marrow Transplantation Group. We have published it since October 2018 and issue quarterly. Blood Cell Therapy was listed on PubMed Central (PMC) on January 20, 2023.

Online ISSN: 2432-7026

Journal homepage: <https://bct.apbmt.org/>

Aims and scope: Blood Cell Therapy is an international journal publishing peer-reviewed original and review articles in the field of all aspects of hematopoietic cell transplantation and cell therapy. Not only clinical research but also basic research relevant to cell therapy are covered. The scope of our journal encompasses wide variety of clinical or basic topics including:

- Results of trials with new protocols
- Transplant-related complications
- Transplant outcome studies dealing with QOL, psychology, economy or regional characteristics
- Prognostic analysis based on biomarkers
- Translational research
- Transplantation immunology
- Cellular or gene therapy

Submission status of Blood Cell Therapy as of December 31, 2023

	2017	2018	2019	2020	2021	2022	2023
Total Submitted	2	11	17	23	25	22	41
Total Decisioned							
Accept	1	9	12	17	21	19	18
Reject	1	2	3	6	3	3	9
Ongoing	0	0	0	0	0	0	9
Acceptance Rate	50%	82%	71%	74%	84%	86%	-
Article type							
State of the Art					7	6	3
Original Article	1	3	5	14	8	9	23
Review Article	0	3	2	1	2		
Case Report	1	4	4	6	6	3	10
Short Communication	0	1	2	1	2	4	4
Survey Report	0	0	4				1
Guideline				1			

Authors by country/region

	2017	2018	2019	2020	2021	2022	2023	Total
Australia		1	1		1			3
Bangladesh			1					1
Canada				1				1
China		1		1			1	3
India			2	6	4	8	16	36
Indonesia	1		1				1	3
Iran							1	1
Japan	1	7	6	8	9	11	15	57
Korea		1	1		1		1	4
Malaysia			1	2	1			4
Myanmar			1					1
Pakistan				1				1
Philippines				1	3	2		6

Singapore	1	2	2	4	9
Sri Lanka	1				1
Taiwan		1		1	2
Thailand			1		1
Vietnam			1		1
Germany			1		1
United Kingdom	1				1
United States	1				1
Jordan				1	1
Russia				1	1

Editorial Award of Blood Cell Therapy 2023

Alvin Ng Yu-Jin	Human leukocyte antigen allele and haplotype frequencies in Singapore bone marrow donors and cord blood units Volume 5 (2022) Issue 4 No.2 Pages 99-106 https://doi.org/10.31547/bct-2022-004
Ross Salvaris	T-cell replete Haplo-identical HSCT with Post transplant Cyclophosphamide for Hemoglobinopathies: A retrospective analysis from a single center Volume 5 (2022) Issue 2 No.4 Pages 61-68 https://doi.org/10.31547/bct-2021-019
Shohei Nakajima	Quality of life and informational needs for allogeneic hematopoietic stem cell transplant among patients and their caregivers visiting long-term follow-up clinic Volume 5 (2022) Issue 2 No.1 Pages 35-44 https://doi.org/10.31547/bct-2021-005

Editorial Board Member List

Name	Commission	Country
Yoshiki Akatsuka	Editor-in-Chief	Japan
Tatsuo Ichinohe	Deputy Editor-in-Chief	Japan
Jeffrey Szer	Associate Editors	Australia
David Yeung		Australia
Haowen Xiao		China
Navin Khattry		India
Auro Viswabandya		India
Maryam Behfar		Iran
Ayami Yoshimi		Germany /Japan
Satoshi Takahashi		Japan
Junya Kanda		Japan
Shinichiro Okamoto		Japan
Jae Yong Kwak		Korea
Hee-Je Kim		Korea
Mickey Boon Chai Koh		Singapore
William YK Hwang		Singapore
Mei Zhang		China
Yuqian Sun		China
Alok Srivastava		India
Amir Hamidieh		Iran
Mahmoud Aljurf		Saudi Arabia
Daniel Weisdorf		USA
Minako Iida	Editorial Office	Japan
Yukari Nakao	Editorial Office	Japan
Shinobu Herron	Editorial Office	Japan

Note: As of the end of 2023

Information for Submission

Manuscript submission rules for Authors : https://bct.apbmt.org/for_authors/

Editorial Policies : https://bct.apbmt.org/editorial_policies/

Guide for Reviewers : https://bct.apbmt.org/for_reviewers/

Submission : <https://mc.manuscriptcentral.com/bct>

List of the Accepted Articles Vol.6

Case Report

Pulmonary veno-occlusive disease after respiratory syncytial virus infection in a post hematopoietic stem cell transplantation patient

Tatsuo Watanabe, Kazutoshi Komori, Shoji Saito, Eriko Uchida, Takashi Kurata, Masatomo Kitamura, Hikoro Matsui, Kohta Takei, Yoshifumi Ogiso, Keiko Ohta-Ogo, Yozo Nakazawa, Kazuo Sakashita

Blood Cell Therapy Volume 6 (2023) Issue 1 No.1 Pages 1-4

DOI:<https://doi.org/10.31547/bct-2022-005>

Original Article

Allogeneic stem cell transplant for myelofibrosis- A retrospective single-center study

Dharma Choudhary, Divya Doval, Vipin Khandelwal, Rasika Setia, Anil Handoo

Blood Cell Therapy Volume 6 (2023) Issue 1 No.2 Pages 5-10

DOI:<https://doi.org/10.31547/bct-2022-003>

Original Article

Motivation for physical activity before and after allogeneic hematopoietic stem cell transplantationFactors

Kimiko Nakano, Shiro Fujii, Reiko Yamahana, Chiemi Onishi

Blood Cell Therapy Volume 6 (2023) Issue 1 No.3 Pages 11-17

DOI:<https://doi.org/10.31547/bct-2022-016>

Short Communication

Utility of eGVHD App for bedside GVHD assessment in a high-volume BMT center

Prashant Chhabra, Kripa Shanker Kasudhan, Niranjana Khair, Shaweta Kaundal, Madhu Chopra, Charanpreet Singh, Aditya Jandial, Arihant Jain, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra, Deepesh P. Lad

Blood Cell Therapy Volume 6 (2023) Issue 1 No.4 Pages 18-22

DOI:<https://doi.org/10.31547/bct-2022-017>

State of the Art

Post-Transplant Complications

Khalid Halahleh, Yasuyuki Arai, Eleni Gavrilaki

Blood Cell Therapy Volume 6 (2023) Issue 1 No.5 Pages 23-29

DOI:<https://doi.org/10.31547/bct-2022-021>

Original Article

Outcomes of allogeneic stem cell transplantation for patients with hematologic diseases ≥60 years old

Takahiro Shima, Ken Takigawa, Sae Utsumi, Teruhiko Yoshino, Megumi Naganuma, Mariko Minami, Masayasu Hayashi, Yayoi Matsuo, Takuro Kuriyama, Tetsuya Eto

Blood Cell Therapy Volume 6 (2023) Issue 2 No.1 Pages 30-41

DOI:<https://doi.org/10.31547/bct-2022-018>

State of the Art

Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation

Takanori Teshima, Jaap Jan Boelens, Ken-ichi Matsuoka

Blood Cell Therapy Volume 6 (2023) Issue 2 No.2 Pages 42-48

DOI:<https://doi.org/10.31547/bct-2022-023>

Case Report

A case of severe oral mucosal GVHD induced by heterologous SARS-CoV-2 vaccination after cord blood transplantation

Kazuhiro Sanda, Shigeo Fuji, Hidetoshi Satomi, Masanori Kitamura, Nao Nishimura, Yuma Tada, Yasuhiro Shingai, Sayako Yuda, Takafumi Yokota, Jun Ishikawa.

Volume 6 (2023) Issue 2 No.3 Pages 49-53

DOI:<https://doi.org/10.31547/bct-2021-019>

Original Article

Safety and Accuracy of Professional Continuous Glucose Monitoring in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Shigeki Nagao, Kimikazu Yakushijin, Ako Higashime, Koji Kawaguchi, Marika Watanabe, Rina Sakai, Hiroya Ichikawa, Yu Mizutani, Hideaki Goto, Seiji Kakiuchi, Keiji Kurata, Akihito Kitao, Yoshiharu Miyata, Yoshinori Imamura, Yushi Hirota, Michiko Takahashi, Shinichiro Kawamoto, Katsuya Yamamoto, Hiroshi Matsuoka, Hironobu Minami.

Blood Cell Therapy Volume 6 (2023) Issue 2 No.4 Pages 54-60

DOI:<https://doi.org/10.31547/bct-2022-024>

Original Article

Role of fluoroquinolone prophylaxis in allogeneic hematopoietic cell transplantation in regions with a high prevalence of fluoroquinolone resistance

Ashwin Nair, Shaweta Kaundal, Kripa Shanker Kasudhan, Madhu Chopra, Charanpreet Singh, Aditya Jandial, Arihant

Jain, Gaurav Prakash, Alka Khadwal, Archana Angrup, Amol Patil, Pallab Ray, Pankaj Malhotra, Deepesh P Lad

Blood Cell Therapy Volume 6 (2023) Issue 2 No.5 Pages 61-65

DOI:<https://doi.org/10.31547/bct-2022-020>

Short Communication

GVHD relapse-free survival after peripheral blood hematopoietic cell transplantation for hematologic malignancies

Deepesh P. Lad, Prashant Chhabra, Kripa Shanker Kasudhan, Shaweta Kaundal, Madhu Chopra, Charanpreet Singh, Aditya Jandial, Arihant Jain, Gaurav Prakash, Alka Khadwal, Pankaj Malhotra.

Blood Cell Therapy Volume 6 (2023) Issue 3 No.1 Pages 66-71

DOI:<https://doi.org/10.31547/bct-2022-014>

Short Communication

Efficacy and safety of plerixafor in pediatric cancer patients undergoing peripheral blood stem cell harvest for autologous hematopoietic stem cell transplant

Aditya Kumar Gupta, Jagdish Prasad Meena, Hem Chandra Pandey, Poonam Coshic, Rachna Seth.

Blood Cell Therapy Volume 6 (2023) Issue 3 No.2 Pages 72-76

DOI:<https://doi.org/10.31547/bct-2022-022>

Case Report

Gilteritinib in peritransplant period for relapsed or refractory FLT3-mutated acute myeloid leukemia: A case report of three patients

Fuka Mima, Shigeo Fuji, Kumi Shibata, Shuhei Kida, Kazuhito Tsutsumi, Yuma Tada, Yasuhiro Shingai, Sayako Yuda, Takafumi Yokota, Jun Ishikawa.

Blood Cell Therapy Volume 6 (2023) Issue 3 No.3 Pages 77-79

DOI:<https://doi.org/10.31547/bct-2023-003>

Original Article

Association of CDKN2A/2B deletion with relapse after hematopoietic stem cell transplantation for acute lymphoblastic leukemia

Makoto Onizuka, Eri Kikkawa, Shinichiro Machida, Masako Toyosaki, Rikio Suzuki, Daisuke Ogiya, Yasuyuki Aoyama, Jun Amaki, Kaito Harada, Ryujiro Hara, Sawako Shiraiwa, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando.

Blood Cell Therapy Volume 6 (2023) Issue 3 No.4 Pages 80-86

DOI:<https://doi.org/10.31547/bct-2023-004>

Original Article

Maintenance therapy with Everolimus in patients with refractory or relapsing Hodgkin lymphoma after autologous stem cell transplantation

Mahshid Mehdizadeh, Hamed Azhdari Tehrani, Hamid Rezvani, Shayan Zamani, Sina Salari, Abbas Hajifathali.

Blood Cell Therapy Volume 6 (2023) Issue 3 No.5 Pages 87-94

DOI:<https://doi.org/10.31547/bct-2023-005>

Original Article

Lenalidomide with or without dexamethasone for relapsed or refractory Hodgkin lymphoma post autologous stem cell transplant

Komal Kumbhalwar, Sachin Punatar, Anant Gokarn, Lingaraj Nayak, Akanksha Chichra, Sumeet Mirgh, Nishant Jindal, Libin Mathew, Navin Khattry.

Blood Cell Therapy Volume 6 (2023) Issue 3 No.6 Pages 95-103

DOI:<https://doi.org/10.31547/bct-2023-009>

Original Article

Long-term Use of Ibrutinib in Japanese Patients with Steroid Dependent/Refractory cGVHD: Final Analysis of Multicenter Study

Masako Toyosaki, Noriko Doki, Souichi Shiratori, Tomoo Osumi, Masaya Okada, Toshiro Kawakita, Masashi Sawa, Takayuki Ishikawa, Yasunori Ueda, Tomoyoshi Hatayama, Nozomi Yoshinari, Ei Fujikawa.

Blood Cell Therapy Volume 6 (2023) Issue 4 No.1 Pages 104-113

DOI:<https://doi.org/10.31547/bct-2023-010>

Original Article

Report on hematopoietic cell transplantations performed in 2018/2019 focusing on the trends of selection of stem cell sources in the Asia-Pacific region: APBMT Activity Survey

Minako Iida, Kaiyan Liu, Xiao Jun Huang, He Huang, Yachiyo Kuwatsuka, Joon Ho Moon, Jong Wook Lee, Kavitha M. Lakshmi, Anthony Dodds, Leonie Wilcox, Bor-Sheng Ko, Amir Ali Hamidieh, Maryam Behfar, Kim Wah Ho, Udomsak Bunworasate, Aloysius Ho, Tasneem Farzana, Joycelyn Sim, Phu Chi Dung, Mafruha Akter, Wasantha Ratnayake, Marjorie Rose Bravo, Aye Aye Gyi, Damai Santosa, Bishesh Sharma Poudyal, Khishigjargal Batshkh, Alok Srivastava, Shinichiro Okamoto, Yoshiko Atsuta.

Blood Cell Therapy Volume 6 (2023) Issue 4 No.2 Pages 114-123

DOI:<https://doi.org/10.31547/bct-2023-015>

Short Communication

Factors Impacting Return to Work/School among Hematopoietic Cell Transplantation Survivors in India

Andrew Pardeep, Urmimala Bhattacharjee, Ritika Sharma, Renaisa De, Charanpreet Singh, Shaweta Kaundal, Madhu Chopra, Aditya Jandial, Arihant Jain, Gaurav Prakash, Alka Khadwal, Navneet Majhail, Pankaj Malhotra, Deepesh Lad.

Blood Cell Therapy Volume 6 (2023) Issue 4 No.3 Pages 124-128

DOI:<https://doi.org/10.31547/bct-2023-017>

Original Article

Early prediction of cytokine release syndrome by measuring phosphate and magnesium levels following chimeric antigen receptor T cell therapy

Masahiro Yoshida, Yoshinori Matsuoka, Satoshi Mitsuyuki, Noboru Yonetani, Junichi Kawai, Tadakazu Kondo, Takayuki Ishikawa.

Blood Cell Therapy Volume 6 (2023) Issue 4 No.4 Pages 129-134

DOI:<https://doi.org/10.31547/bct-2023-021>

Case Report

Three cases of suspected pleuroparenchymal fibroelastosis after allogeneic hematopoietic cell transplantation

Shiori Morikawa, Nobuaki Fukushima, Tomoya Arakawa, Tomoki Fujii, Shuto Negishi, Yuma Kawamura, Miyo Goto, Kazutaka Ozeki, Akio Kohno.

Blood Cell Therapy Volume 6 (2023) Issue 4 No.5 Pages 135-138

DOI:<https://doi.org/10.31547/bct-2023-018>

Survey Report

Impact of the COVID-19 pandemic on hematopoietic stem cell transplant programmes in Singapore

Timothy Lam Jia Rong, Gayathri Basker, Chan Yong Hoe, Than Hein, Li Mei Michelle Poon, Goh Yeow Tee.

Blood Cell Therapy Volume 6 (2023) Issue 4 No.6 Pages 139-144

DOI:<https://doi.org/10.31547/bct-2023-019>

State of the Art

Chimeric Antigen Receptor T Cell Therapy for Acute Leukemia

Jing Pan

Blood Cell Therapy Volume 6 (2023) Issue 4 No.7 Pages 145-150

DOI:<https://doi.org/10.31547/bct-2023-028>

State of the Art

Recent advances in ex vivo expansion of human hematopoietic stem cells

Masatoshi Sakurai

Blood Cell Therapy Volume 6 (2023) Issue 4 No.8 Pages 151-157

DOI:<https://doi.org/10.31547/bct-2023-026>

Appendix

Cooperate Members

Annual sponsorship	Center for Supporting Hematology-Oncology Trials (C-SHOT) in Japan
International sponsorship for the APBMT 2023 Indonesia	Jazz
	Gilead Sciences
	Miltenyi Biotec
	Takeda
Banner sponsorship	KYOWA KIRIN
	Otsuka
	SymBio
	Janssen

APBMT Annual Report 2023

Secretariat office

E-mail: office@apbmt.org

Website: <https://www.apbmt.org>

Department of Promotion for Blood and Marrow
Transplantation

Aichi Medical University School of Medicine

1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan

Tel: +81 561 62 3311 (Ext. 12375) Fax: +81 561 61 3180



Minako Iida

miida@aichi-med-u.ac.jp



Yukari Nakao

yukari-nakao@aichi-med-u.ac.jp



Shinobu Herron

Shinobu.herron@aichi-med-u.ac.jp

